

November 9, 2023

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir,

Sub: Press Release on Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2023.

We enclose a copy of the Press Release on Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2023.

Please take the information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

Enclosures: as above.

Press Release

Investor Relations | Corporate Communications
Phone: 040-66721551 / 66725000
Email: ir@aurobindo.com

Hyderabad, India, November 9th, 2023: Aurobindo Pharma Limited (BSE: 524804 and NSE: AUROPHARMA) ("Aurobindo") today announced its consolidated financial results for the quarter ended September 30, 2023.

Aurobindo Pharma Ltd. Q2FY24 Consolidated Financial Results

Amount (INR Cr)	Q2FY24	Q2FY23	% Change YoY	Q1FY24	% Change QoQ
Revenue from operations	7,219	5,739	25.8%	6,851	5.4%
EBITDA before Forex and Other Income	1,403	837	67.7%	1,151	21.9%
EBITDA margin (%)	19.4%	14.6%	486 bps	16.8%	263 bps
PBT before share of P/L of JV, Forex, and Exceptional items	1,105	571	93.6%	847	30.4%
Net Profit after Share of Profit/Loss of JV and minority interest	752	409	83.6%	571	31.7%

Key highlights of Q2FY24

- Revenue from Operations increased by 25.8% YoY to INR 7,219 Cr with growth seen across key segments
- US formulations (excluding Puerto Rico) revenue increased by 35.7% YoY to INR 3,385 Cr (USD 409 million)
- Europe formulation revenue increased by 16.7% YoY to INR 1,769 Cr (EUR 197 million)
- Growth Markets revenue increased by 24.7% YoY to INR 564 Cr (USD 68 million)
- ARV revenue increased by 52.1% YoY to INR 250 Cr (USD 30 million)
- API revenue grew by 20.3% YoY to INR 1,166 Cr
- EBITDA before Forex and Other income stood at INR 1,403 Cr; EBITDA margin of 19.4 %
- Research & Development (R&D) spend stood at INR 300 Cr, 4.2% of revenues (vs. Q1 FY24: 5.7%)
- Received final approval for 15 ANDAs including 3 injectable products from the USFDA
- Net Profit after Share of Profit/Loss of JV and minority interest at INR 752 Cr, vs. INR 409 Cr in Q2FY23
- Basic & Diluted EPS grew by 83.6% YoY to INR 12.83 per share
- Board has approved interim dividend @ 300% i.e. INR 3 per equity share of INR 1/- for the year FY23-24


Commenting on the Company's performance, Mr. K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: "This is yet another quarter with highest ever sales, driven by robust performance across the markets, and continued margin expansion, aided by operational leverage and efficiencies. With our strong product pipeline, focus on compliance and key projects in advanced stages, we will continue our growth journey, while generating value for our stakeholders."

Operational Performance (Consolidated)

₹ Cr	Q2FY24	Q2FY23	Y-o-Y (%)	Q1FY24	Q-o-Q (%)
USA	3,385	2,495	35.7%	3,137	7.9%
Europe	1,769	1,516	16.7%	1,837	-3.7%
Growth Markets	564	452	24.7%	475	18.6%
ARV	250	164	52.1%	201	24.4%
Total Formulations	5,968	4,627	29.0%	5,650	5.6%
Betalactam	816	636	28.4%	719	13.5%
Non Betalactam	350	334	5.0%	314	11.5%
Total API	1,166	969	20.3%	1,033	12.9%
Consolidated Gross sales (Ex- Puerto Rico)	7,134	5,597	27.5%	6,683	6.7%
Puerto Rico	85	143	-40.3%	167	-49.0%
Revenue from operations	7,219	5,739	25.8%	6,851	5.4%

*includes domestic formulation sales of INR 66 Cr in Q2 FY24

Q2FY24: Consolidated revenue breakup - Geography & Segment wise



Q2 FY24 performance

Formulation revenue increased by 29.0% YoY to INR 5,968 Cr

US Formulations

- US revenue increased by 35.7% YoY to INR 3,385 Cr and accounted for 46.9% of consolidated revenue
- In USD terms, revenue increased by 30.7% YoY to USD 409 million
- Filed 10 ANDAs with USFDA during the quarter
- Received final approval for 15 ANDAs including 3 injectable products during the quarter
- As on 30th September 2023, on a cumulative basis, the company has filed 817 ANDAs with USFDA and received 628 final approval and 32 tentative approval
- The company has launched 19 products including 5 injectables during the quarter

Europe Formulations

- Europe revenue increased by 16.7% YoY to INR 1,769 Cr and accounted for 24.5% of consolidated revenue
- In Euro terms, revenue increased by 4.0% YoY to EUR 197 million

Growth Markets Formulations

- Growth Markets formulations revenue increased by 24.7% YoY to INR 564 Cr and accounted for 7.8% of consolidated revenue
- In USD terms, revenue increased by 20.1% YoY to USD 68 million
- Domestic formulation sales in Q2 FY24 was INR 66 Cr

ARV Formulations

- ARV business revenue increased by 52.1% YoY to INR 250 Cr and accounted for 3.5% of consolidated revenue
- In USD terms, revenue increased by 46.4% YoY to USD 30 million

Active Pharmaceutical Ingredients (API)

- API business revenue increased by 20.3% to INR 1,166 Cr and contributed 16.2% of consolidated revenue

Global Regulatory Filings

Details	Q2FY24	Cumulative Filings as on 30 th September 2023
ANDAs (including filings from Aurobindo USA)	10	817
DMFs (including filings from Eugia and Auro Peptides)	4	280
Formulations Dossiers in other key advanced markets (incl. multiple registrations in Europe, South Africa and Canada)	51	4,492
API filings in other key regulated markets (incl. multiple registrations)	4	3,734

Final USFDA Approvals Received in Q2 FY24

Received by Aurobindo Pharma Limited

#	Product	Strength	Therapy area
1	Ramelteon Tablets	8 mg	Central Nervous System
2	Sevelamer Hydrochloride Tablets	400 mg and 800 mg	Phosphate Binder
3	Esomeprazole Magnesium Delayed-Release Tablets	20 mg	Gastrointestinal
4	Ertugliflozin Tablets	5 mg and 15 mg	Anti-Diabetic
5	Hydrocortisone Tablets USP	5 mg, 10 mg and 20 mg	Steroid (Glucocorticoid)
6	Apremilast Tablets	10 mg, 20 mg and 30 mg	Musculoskeletal Agent
7	Saxagliptin Tablets	2.5 mg and 5 mg	Anti-Diabetic
8	Fluphenazine Hydrochloride Tablets USP	1 mg, 2.5 mg, 5 mg and 10 mg	Central Nervous System
9	Loperamide Hydrochloride Capsules USP	2 mg	Gastrointestinal
10	Ibuprofen Capsules (Minis) (OTC)	200 mg	Pain Relief
11	Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules USP	5 mg/2.5 mg	Gastrointestinal
12	Topiramate Capsules USP	15 mg and 25 mg	Central Nervous System

Received by Eugia Pharma Specialities

#	Product	Strength	Therapy area
1	Plerixafor Injection [Single-Dose Vial]	24 mg/1.2 mL (20 mg/mL)	Hematopoietic Stem Cell Mobilizer
2	Vancomycin Hydrochloride for Injection USP [Single-Dose Vial]	1.25 g/vial and 1.5 g/vial	Antibacterial Agent
3	Icatibant Injection [Single-Dose Prefilled Syringe]	30 mg/3 mL (10 mg/mL)	Bradykinin B2 Receptor Antagonist

Q2FY24 Earnings Call Details

The company will host an earnings call at **8.30 AM IST on 10th November 2023**, to discuss the performance and answer any questions from participants.

To join the call through Zoom, please pre-register using the link: <https://bit.ly/3tVVB9b>

About Aurobindo Pharma Limited

Aurobindo Pharma Limited (www.aurobindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) headquartered at Hyderabad, India, develops, manufactures, and distributes generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, EU, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company's robust product portfolio is spread over therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up. The Company is marketing these products globally in over 150 countries.

For Further Information, please contact:

Investor Relations | Corporate Communications

Phone: 040-66721551 / 66725000

Email: ir@aurobindo.com